Skip to main content
. Author manuscript; available in PMC: 2021 Jun 1.
Published in final edited form as: Clin Cancer Res. 2020 Sep 30;26(23):6299–6309. doi: 10.1158/1078-0432.CCR-20-1739

Figure 2. Itacitinib reduces IL-6 production by macrophages.

Figure 2.

(A) Macrophages harvested from C57BL-6 mice were treated with increasing doses of itacitinib 1 day in advance of being activated with 5 ng/mL LPS. Twenty-four hours after LPS treatment, supernatant was harvested and cytokine levels measured. (B) C57BL/6 mice were prophylactically orally dosed with vehicle, or 60 or 120 mg/kg of itacitinib b.i.d. for 3 days. Mice then received intraperitoneal injections of LPS (5 μg per animal). Two hours after injection, mice were euthanized and IL-6 levels were measured in the peritoneal lavage. Data represent mean ± SEM, and P values were calculated by two-way ANOVA. *P < 0.05, ***P < 0.001. Data are representative of two independent experiments.